This P/E Suggests GlaxoSmithKline plc is a Buy

GlaxoSmithKline plc (LON:GSK) looks fairly valued but remains a long-term buy, says Roland Head.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 has risen by more than 85% since it hit rock bottom in 2009, and bargains are getting harder to find.

I’m on the hunt for companies that still look cheap, based on their long-term earnings potential. To help me hunt down these bargains, I’m using a special version of the price to earnings ratio called the PE10, which is one of my favourite tools for value investing.

The PE10 compares the current share price with average earnings per share for the last ten years. This lets you see whether a company looks cheap compared to its long-term earnings.

Today, I’m going to take a look at the PE10 of pharmaceutical firm GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

Is Glaxo cheap?

Glaxo is a popular share with income investors, and its size means that it forms a key part of all FTSE 100 trackers. The firm’s shares have outperformed the FTSE this year and are up by 23% so far — more than double the FTSE’s 9% gain.

Given this strong performance, do Glaxo shares still look cheap enough to buy? Let’s take a look at Glaxo’s current price-to-earnings ratio, and its PE10:

GlaxoSmithKline 14.8 20.0

Glaxo’s long-term PE10 of 20.0 looks quite expensive, and suggests that Glaxo is quite fully valued, when compared to its average reported earnings over the last ten years.

However, analysts tend to use adjusted earnings to calculate P/E ratios, and on this measure Glaxo trades on a trailing twelve month P/E of 14.8, slightly lower than the FTSE 100 average of 17.

Analysts’ consensus forecasts suggest that Glaxo’s adjusted earnings will be largely unchanged this year, making its valuation look quite supportable, especially given the pharmaceutical firm’s dividend yield of 4.4%, which is almost 50% more than the FTSE 100 average of 3%.

Is Glaxo a buy?

In my view, Glaxo’s current valuation is reasonable, thanks to its above-average yield and its long-term growth prospects.

Although the firm’s current bribery scandal in China is unfortunate, I don’t believe it will affect Glaxo’s long-term prospects: consumers in emerging markets are gradually going to gain access to Glaxo products that we take for granted, fuelling major long-term growth.

In my view, Glaxo is fairly priced at the moment, but its long-term prospects and income justify a cautious buy rating. I intend to gradually accumulate more Glaxo shares, buying on any temporary dips.

Can you beat the market?

If you already own shares in GlaxoSmithKline, then I’d strongly recommend that you take a look at this special Motley Fool report. Newly updated for 2013, it contains details of top UK fund manager Neil Woodford’s eight largest holdings.

Mr. Woodford’s track record is impressive: if you’d invested £10,000 into his High Income fund in 1988, it would have been worth £193,000 at the end of 2012 — a 1,830% increase!

This special report is completely free, but availability is limited, so click here to download your copy immediately.

> Roland owns shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Mature black couple enjoying shopping together in UK high street
Investing Articles

How much must I invest in Tesco shares to earn income of £1,000 a year in 2024?

Tesco shares have given investors a winning combination of dividend income and share price growth lately. Should I buy them?

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Should I sell underperforming Fundsmith Equity or can Terry Smith beat the world again?

Terry Smith's investment vehicle Fundsmith Equity is heading for a second year of underperformance. Is it time to bail out?

Read more »

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

2 quality growth stocks I’m looking to buy in December

Stephen Wright thinks two growth stocks could be great investments for 2024. One is a FTSE 100 conglomerate, the other…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

Does today’s beaten down Scottish Mortgage share price make it a no-brainer buy?

The crashing Scottish Mortgage share price has marred many a portfolio. Now there's talk of a recovery. Am I in?

Read more »

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

If I could only buy 1 more FTSE income stock in December, I’d grab this ultra-high-yielder

I think I can afford to buy one more FTSE 100 income stock before the end of the year. My…

Read more »

Abstract 3d arrows with rocket
Investing Articles

I think these are my best growth shares to buy with £1,000

Jon Smith talks through some shares to buy that he likes for next year, with a particular focus on retail…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

2 terrific cheap shares I’d snap up before it’s too late!

Our writer wants to capitalise on cheap shares now before any potential market rally and identifies a couple of stocks…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Investing Articles

While the US stock market booms, the FTSE 100 lags behind. Or does it?

In November, global stock markets had their best month in over three years. Meanwhile, the UK's Footsie keeps falling further…

Read more »